DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for sideroblastic anemia 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSideroblastic anemia 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sideroblastic anemia 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glutaredoxin 5 (GLRX5) — GLRX5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gshdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2WUL · 2.4 Å · ligand Glutathione (GSH). Experimental structure, not a prediction.
What the evidence adds up to
Sideroblastic anemias are a heterogeneous group of disorders whose unifying feature is the ring sideroblast, a pathological erythroid precursor with excessive deposits of non-heme iron in mitochondria that create a perinuclear ring appearance. The condition may be hereditary or acquired. Hereditary forms are caused by defects in genes on the X chromosome (ALAS2, ABCB7, GRLX5), autosomal chromosomes, or mitochondrial genes. Acquired sideroblastic anemias are either primary, such as refractory anemia with ring sideroblasts (RARS) which is a subtype of myelodysplastic syndrome, or secondary to drugs, toxins, copper deficiency, or chronic neoplastic disease. The pathogenesis of mitochondrial iron loading in developing erythroblasts is diverse and can result from a heme synthesis defect, a defect in iron-sulfur cluster assembly, a defect in iron-sulfur protein precursor release from mitochondria, or a defect in intracellular iron metabolism in erythroid cells.
A 1995 letter reported a single 19-year-old man with sideroblastic anemia who was treated with chloroquine. At presentation his hemoglobin was 5 g per deciliter, and bone marrow showed 60 ringed sideroblasts per 100 erythroid cells. The letter states he was successfully treated, but provides no numerical outcomes, no follow-up duration, and no control. This is a single case report with no generalisable evidence.
A 2025 review states that management is etiology-driven. Hereditary forms, often involving ALAS2 mutations, may respond to pyridoxine (Vitamin B6). Acquired reversible causes such as copper deficiency, alcohol, or drugs require removal of the insult. Clonal MDS-RS variants are managed with erythropoiesis-stimulating agents, luspatercept, or hypomethylating agents. Iron overload is a universal complication that requires monitoring and chelation or phlebotomy. The review does not report any new trial data, response rates, or survival numbers.
What is still missing are prospective clinical trials that test specific drugs against defined genetic subtypes of sideroblastic anemia, with adequate sample sizes and long-term follow-up. There is no randomised evidence for chloroquine, no validated stratification of patients by molecular lesion, and no funding commitment to move beyond single case reports and narrative reviews.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acta Haematologica · 2009 · 41 citations
Mitochondrial Iron Metabolism and Sideroblastic Anemia
AbstractSideroblastic anemias are a heterogeneous group of disorders, characterized by mitochondrial iron overload in developing red blood cells. The unifying characteristic of all sideroblastic anemias is the ring sideroblast, which is a pathological erythroid precursor containing excessive deposits of non-heme iron in mitochondria with perinuclear distribution creating a ring appearance. Sideroblastic anemias may be hereditary or acquired. Hereditary sideroblastic anemias are caused by defects in genes present on the X chromosome (mutations in the ALAS2, ABCB7, or GRLX5 gene), genes on autosomal chromosomes, or mitochondrial genes. Acquired sideroblastic anemias are either primary (refractory anemia with ring sideroblasts, RARS, representing one subtype of the myelodysplastic syndrome) or secondary due to some drugs, toxins, copper deficiency, or chronic neoplastic disease. The pathogenesis of mitochondrial iron loading in developing erythroblasts is diverse. Ring sideroblasts can develop as a result of a heme synthesis defect in erythroblasts (ALAS2 mutations), a defect in iron-sulfur cluster assembly, iron-sulfur protein precursor release from mitochondria (ABCB7 mutations), or by a defect in intracellular iron metabolism in erythroid cells (e.g. RARS).
New England Journal of Medicine · 1995 · 8 citations
Treatment of Sideroblastic Anemia with Chloroquine
AbstractTo the Editor: The mainstay of treatment for sideroblastic anemia, a group of heterogeneous disorders1,2 involving a defect in heme synthesis,3 is transfusion. We describe a 19-year-old man with sideroblastic anemia who was successfully treated with chloroquine. The patient was referred to our institution in 1984 because of anemia. The white-cell count was 8.6×109 per liter, the platelet count 350×109 per liter, the hemoglobin level 5 g per deciliter, the mean cell volume 86 μm3, and the reticulocyte count 11×103 per liter. In the bone marrow, erythroid cellularity was normal, but there were 60 ringed sideroblasts per 100 . . .
Saudi Journal of Medicine and Public Health · 2025 · 0 citations · open access
Sideroblastic Anemia: Laboratory Evaluation, Diagnostic Challenges, and Clinical Correlation
AbstractBackground: Sideroblastic anemia (SA) is a heterogeneous group of disorders unified by the pathological hallmark of ring sideroblasts—erythroid precursors with perinuclear mitochondrial iron accumulation visible on Prussian blue-stained bone marrow aspirates. This results from defective heme synthesis, leading to ineffective erythropoiesis and a characteristic paradox of systemic iron overload concurrent with anemia. Aim: This article provides a comprehensive review of the laboratory evaluation, diagnostic challenges, and clinical management of sideroblastic anemia. It aims to delineate the pathophysiologic pathways, categorize the diverse etiologies, and correlate diagnostic findings with appropriate therapeutic strategies. Methods: A detailed analysis of the etiology, pathophysiology, and histopathology of SA is presented. The diagnostic approach integrates complete blood count, iron studies, peripheral smear for siderocytes, and definitive bone marrow examination. Further classification relies on genetic testing for hereditary forms and molecular analysis (e.g., for SF3B1 mutations) for acquired, clonal variants like myelodysplastic syndromes with ring sideroblasts (MDS-RS). Results: Management is etiology-driven. Hereditary forms, often involving ALAS2 mutations, may respond to pyridoxine (Vitamin B6). Acquired, reversible causes (e.g., copper deficiency, alcohol, drugs) require removal of the insult. Clonal MDS-RS variants are managed with erythropoiesis-stimulating agents, luspatercept, or hypomethylating agents. Iron overload, a universal complication, necessitates vigilant monitoring and chelation or phlebotomy to prevent end-organ damage. Conclusion: Accurate diagnosis of SA hinges on marrow morphology and systematic evaluation to distinguish between congenital, acquired, and clonal causes, which is crucial for implementing targeted therapy and managing iron overload to improve patient outcomes.
American Journal of Hematology · 1998 · 0 citations
Sideroblastic anemias: Variations on imprecision in diagnostic criteria, proposal for an extended classification of sideroblastic anemias
AbstractSideroblastic anemias are caused by a diversity of hereditary, congenital, or acquired disorders.Criteria used in describing sideroblastic anemias vary widely among standard medical textbooks and even so have been imprecisely applied in the literature.Recent discoveries concerning the basic pathophysiologic mechanisms involving the molecular biology of nuclear and mitochondrial DNA, erythroid ALA synthase (ALAS-2), and iron transport have made the classification of sideroblastic anemias very complex.We recommend a more precise evaluation and documentation of the components that characterize the sideroblastic abnormality and propose an extended classification of the sideroblastic anemias.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
